Synopsis A recent clinical study demonstrates that RAS-modification may be key in regulating oxidative damage and chronic inflammation in patients with chronic illness. This week's 'MED FACT' discusses a clinical trial from Clinical diabetes and endocrinology , “ Renin Angiotensin system-modifying therapies are associated with improved pulmonary health ”. 2018. Authors : Soto M; Bang SI; McCombs J; Rodgers KE.
Key Takeaways There is an association between the use of ACE-Is and ARBs and a delay in the progression of pulmonary complications in vulnerable populations. Objective Study Type Participants To evaluate the effect of RAS-modifying drugs on pulmonary outcomes Retrospective cohort study 215,225 What Was The Need For This Study? Modifiers of RAS may directly impact patient health beyond hypertension (HTN) regulation. Activation of the pathological arm of the RAS by…
